Bevacizumab-400mg/16ml(Cizumab)
Bevacizumab 400mg Injection (Cizumab) is a targeted anti-cancer therapy that blocks tumor blood vessel growth. It works by inhibiting VEGF, slowing cancer progression effectively. Commonly used for colorectal, lung, and kidney cancers, it enhances treatment outcomes when combined with chemotherapy. Manufactured under high-quality standards, it ensures safety and effectiveness. Administered under medical supervision, it provides reliable and advanced cancer care support.
Description
Bevacizumab 400mg Injection is a highly effective targeted therapy designed to inhibit the growth of blood vessels that supply tumors. Marketed as Cizumab, this advanced monoclonal antibody works by blocking vascular endothelial growth factor (VEGF), thereby restricting tumor nourishment and slowing cancer progression. It is widely used in the treatment of various cancers, including colorectal cancer, lung cancer, kidney cancer, and glioblastoma.
This injectable formulation ensures precise dosing and rapid therapeutic action, making it a preferred choice among oncologists. Bevacizumab 400mg/16ml helps improve patient outcomes when used alone or in combination with chemotherapy. Its mechanism focuses on cutting off the tumor’s blood supply, which reduces its ability to grow and spread.
Cizumab is manufactured under strict quality standards, ensuring safety, potency, and reliability. It is administered under medical supervision, ensuring optimal results and minimized side effects. Patients benefit from improved survival rates and better disease management when using this therapy as part of a comprehensive cancer treatment plan.
This product is ideal for healthcare providers seeking advanced biologic treatments that deliver targeted action with proven clinical benefits. With its trusted formulation and effectiveness, Bevacizumab 400mg Injection stands as a reliable option in modern oncology care.
Cizumab plays a crucial role in combination therapy regimens, where it enhances the effectiveness of other anti-cancer drugs. It helps shrink tumors, delays disease progression, and improves overall treatment response rates. Its consistent performance in clinical oncology has made it a trusted choice among healthcare professionals worldwide.
Patients receiving Bevacizumab 400mg Injection often experience better disease control, especially in advanced or metastatic cancers. The formulation supports long-term treatment plans, offering sustained therapeutic benefits when administered as prescribed. Additionally, its compatibility with various chemotherapy protocols increases its versatility in cancer care.
- Brand Name: Cizumab
- Generic Name: Bevacizumab
- Strength: 400mg/16ml
- Form: Injection
- Category: Anti-Cancer / Monoclonal Antibody
- Mechanism: VEGF Inhibitor
- Usage: Various cancers (colorectal, lung, kidney, brain)
- Administration: Intravenous (under medical supervision)
- Storage: Store in a cool, dry place (2°C–8°C)
